Naveen Kanathur, MD
Pulmonary Disease · Bettendorf, IANPI 1326043514
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,045 of the $13,628 with a category attached, or 66.4%. Intuitive Surgical accounts for 72.2% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $10,214, 9.9 times the $1,030 reported in 2019.
Across 101 payments — averaging $134.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Covidien LP$651
- Harmony Biosciences LLC$472
- Noah Medical Corporation$314
- Boehringer Ingelheim$289
- Inspire Medical Systems, Inc.$259
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,53411%
- Food & beverage$3,04922%
- Education$9,04566%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $9,841 |
| Covidien LP | 2 | $651 |
| Harmony Biosciences LLC | 23 | $472 |
| Noah Medical Corporation | 1 | $314 |
| Boehringer Ingelheim | 7 | $289 |
| Inspire Medical Systems, Inc. | 6 | $259 |
| Regeneron Healthcare Solutions, Inc. | 4 | $256 |
| Jazz Pharmaceuticals Inc. | 3 | $246 |
| United Therapeutics Corporation | 3 | $190 |
| Sanofi | 4 | $135 |
| Chiesi USA, Inc. | 1 | $132 |
| Lantheus Medical Imaging, Inc. | 1 | $112 |
| Actelion Pharmaceuticals US, Inc. | 2 | $98 |
| Verona Pharma, Inc. | 3 | $97 |
| Itamar Medical Inc | 2 | $77 |
| Veran Medical Technologies, Inc. | 1 | $69 |
| Baxter Healthcare | 2 | $43 |
| Resmed Corp | 1 | $42 |
| Pulmonx Corporation | 2 | $39 |
| ERBE USA Inc | 1 | $39 |
| Mylan Specialty L.p. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 1 | $30 |
| Johnson & Johnson | 2 | $29 |
| ZOLL Respicardia, Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $26 |
| AstraZeneca | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Insmed, Inc. | 1 | $16 |
| Circassia Inc. | 1 | $11 |
| Inogen, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,327
- superDimension$635
- GALAXY$314
- TYVASO$157
- Inspire$135
- XYWAV$127
- Definity$112
- Wakix$105
- SUNOSI$103
How this compares
$13,628 in reported general payments places this provider in the 85th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $424,883 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 580 | $423,623 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 462 | $247,252 |
| Spiriva RespimatTiotropium Bromide | 256 | $156,250 |
| Pirfenidone | 37 | $135,460 |
| Dupixent PenDupilumab | 22 | $91,212 |
| NucalaMepolizumab | 18 | $87,529 |
| Spiriva HandihalerTiotropium Bromide | 92 | $79,161 |
| Breo ElliptaFluticasone/Vilanterol | 163 | $76,273 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 83 | $60,515 |
| Incruse ElliptaUmeclidinium Bromide | 131 | $48,913 |
| SymbicortBudesonide/Formoterol Fumarate | 148 | $47,583 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $45,573 |
| EliquisApixaban | 59 | $41,004 |
| Advair HfaFluticasone Propion/Salmeterol | 89 | $30,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $289 | $651,506383 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $22 | $134,888297 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Bettendorf
- Michael HoffmanBettendorf$550
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
- Matthew TrumpWest Des Moines$41K
- Brian WittDavenport$19K
- Shrey VelaniDes Moines$18K
- James MallenWest Des Moines$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.